Cargando…

Modelling amyotrophic lateral sclerosis: progress and possibilities

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that primarily affects the motor system and presents with progressive muscle weakness. Most patients survive for only 2-5 years after disease onset, often due to failure of the respiratory muscles. ALS is a familial disease in ∼10%...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Damme, Philip, Robberecht, Wim, Van Den Bosch, Ludo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Company of Biologists Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451175/
https://www.ncbi.nlm.nih.gov/pubmed/28468939
http://dx.doi.org/10.1242/dmm.029058
_version_ 1783240127986794496
author Van Damme, Philip
Robberecht, Wim
Van Den Bosch, Ludo
author_facet Van Damme, Philip
Robberecht, Wim
Van Den Bosch, Ludo
author_sort Van Damme, Philip
collection PubMed
description Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that primarily affects the motor system and presents with progressive muscle weakness. Most patients survive for only 2-5 years after disease onset, often due to failure of the respiratory muscles. ALS is a familial disease in ∼10% of patients, with the remaining 90% developing sporadic ALS. Over the past decade, major advances have been made in our understanding of the genetics and neuropathology of ALS. To date, around 20 genes are associated with ALS, with the most common causes of typical ALS associated with mutations in SOD1, TARDBP, FUS and C9orf72. Advances in our understanding of the genetic basis of ALS have led to the creation of different models of this disease. The molecular pathways that have emerged from these systems are more heterogeneous than previously anticipated, ranging from protein aggregation and defects in multiple key cellular processes in neurons, to dysfunction of surrounding non-neuronal cells. Here, we review the different model systems used to study ALS and discuss how they have contributed to our current knowledge of ALS disease mechanisms. A better understanding of emerging disease pathways, the detrimental effects of the various gene mutations and the causes underlying motor neuron denegation in sporadic ALS will accelerate progress in the development of novel treatments.
format Online
Article
Text
id pubmed-5451175
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The Company of Biologists Ltd
record_format MEDLINE/PubMed
spelling pubmed-54511752017-06-01 Modelling amyotrophic lateral sclerosis: progress and possibilities Van Damme, Philip Robberecht, Wim Van Den Bosch, Ludo Dis Model Mech Review Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that primarily affects the motor system and presents with progressive muscle weakness. Most patients survive for only 2-5 years after disease onset, often due to failure of the respiratory muscles. ALS is a familial disease in ∼10% of patients, with the remaining 90% developing sporadic ALS. Over the past decade, major advances have been made in our understanding of the genetics and neuropathology of ALS. To date, around 20 genes are associated with ALS, with the most common causes of typical ALS associated with mutations in SOD1, TARDBP, FUS and C9orf72. Advances in our understanding of the genetic basis of ALS have led to the creation of different models of this disease. The molecular pathways that have emerged from these systems are more heterogeneous than previously anticipated, ranging from protein aggregation and defects in multiple key cellular processes in neurons, to dysfunction of surrounding non-neuronal cells. Here, we review the different model systems used to study ALS and discuss how they have contributed to our current knowledge of ALS disease mechanisms. A better understanding of emerging disease pathways, the detrimental effects of the various gene mutations and the causes underlying motor neuron denegation in sporadic ALS will accelerate progress in the development of novel treatments. The Company of Biologists Ltd 2017-05-01 /pmc/articles/PMC5451175/ /pubmed/28468939 http://dx.doi.org/10.1242/dmm.029058 Text en © 2017. Published by The Company of Biologists Ltd http://creativecommons.org/licenses/by/3.0This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
spellingShingle Review
Van Damme, Philip
Robberecht, Wim
Van Den Bosch, Ludo
Modelling amyotrophic lateral sclerosis: progress and possibilities
title Modelling amyotrophic lateral sclerosis: progress and possibilities
title_full Modelling amyotrophic lateral sclerosis: progress and possibilities
title_fullStr Modelling amyotrophic lateral sclerosis: progress and possibilities
title_full_unstemmed Modelling amyotrophic lateral sclerosis: progress and possibilities
title_short Modelling amyotrophic lateral sclerosis: progress and possibilities
title_sort modelling amyotrophic lateral sclerosis: progress and possibilities
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451175/
https://www.ncbi.nlm.nih.gov/pubmed/28468939
http://dx.doi.org/10.1242/dmm.029058
work_keys_str_mv AT vandammephilip modellingamyotrophiclateralsclerosisprogressandpossibilities
AT robberechtwim modellingamyotrophiclateralsclerosisprogressandpossibilities
AT vandenboschludo modellingamyotrophiclateralsclerosisprogressandpossibilities